A Phase II Study of Surufatinib Combined With Camrelizumab and mFOLFOX6 as Second-line Treatment for Advanced PRAD
Clinical trial NCT06329947 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT06329947
- Sponsor
- Rui-hua Xu, MD, PhD
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-05-22
- Primary completion
- 2025-01-01
- Enrollment
- 37
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.